BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 20660347)

  • 1. Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9.
    Simmons DP; Canaday DH; Liu Y; Li Q; Huang A; Boom WH; Harding CV
    J Immunol; 2010 Aug; 185(4):2405-15. PubMed ID: 20660347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of dendritic cell antigen cross-presentation by CpG DNA involves type I IFN and stabilization of class I MHC mRNA.
    Kuchtey J; Chefalo PJ; Gray RC; Ramachandra L; Harding CV
    J Immunol; 2005 Aug; 175(4):2244-51. PubMed ID: 16081792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG-B ODNs potently induce low levels of IFN-alphabeta and induce IFN-alphabeta-dependent MHC-I cross-presentation in DCs as effectively as CpG-A and CpG-C ODNs.
    Gray RC; Kuchtey J; Harding CV
    J Leukoc Biol; 2007 Apr; 81(4):1075-85. PubMed ID: 17227820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TLR2 signaling depletes IRAK1 and inhibits induction of type I IFN by TLR7/9.
    Liu YC; Simmons DP; Li X; Abbott DW; Boom WH; Harding CV
    J Immunol; 2012 Feb; 188(3):1019-26. PubMed ID: 22227568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toll-like receptor 9 contributes to recognition of Mycobacterium bovis Bacillus Calmette-Guérin by Flt3-ligand generated dendritic cells.
    von Meyenn F; Schaefer M; Weighardt H; Bauer S; Kirschning CJ; Wagner H; Sparwasser T
    Immunobiology; 2006; 211(6-8):557-65. PubMed ID: 16920494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternate class I MHC antigen processing is inhibited by Toll-like receptor signaling pathogen-associated molecular patterns: Mycobacterium tuberculosis 19-kDa lipoprotein, CpG DNA, and lipopolysaccharide.
    Tobian AA; Potter NS; Ramachandra L; Pai RK; Convery M; Boom WH; Harding CV
    J Immunol; 2003 Aug; 171(3):1413-22. PubMed ID: 12874233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant Lipoprotein Rv1016c Derived from
    Su H; Zhu S; Zhu L; Huang W; Wang H; Zhang Z; Xu Y
    Front Cell Infect Microbiol; 2016; 6():147. PubMed ID: 27917375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Containment of aerogenic Mycobacterium tuberculosis infection in mice does not require MyD88 adaptor function for TLR2, -4 and -9.
    Hölscher C; Reiling N; Schaible UE; Hölscher A; Bathmann C; Korbel D; Lenz I; Sonntag T; Kröger S; Akira S; Mossmann H; Kirschning CJ; Wagner H; Freudenberg M; Ehlers S
    Eur J Immunol; 2008 Mar; 38(3):680-94. PubMed ID: 18266299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent inhibition of macrophage responses to IFN-gamma by live virulent Mycobacterium tuberculosis is independent of mature mycobacterial lipoproteins but dependent on TLR2.
    Banaiee N; Kincaid EZ; Buchwald U; Jacobs WR; Ernst JD
    J Immunol; 2006 Mar; 176(5):3019-27. PubMed ID: 16493060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toll-like receptor 9 is required for full host resistance to Mycobacterium avium infection but plays no role in induction of Th1 responses.
    Carvalho NB; Oliveira FS; Durães FV; de Almeida LA; Flórido M; Prata LO; Caliari MV; Appelberg R; Oliveira SC
    Infect Immun; 2011 Apr; 79(4):1638-46. PubMed ID: 21300776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of cross-priming of naive CD8+ T lymphocytes by recombinant bacillus Calmette-Guerin that secretes heat shock protein 70-major membrane protein-II fusion protein.
    Mukai T; Maeda Y; Tamura T; Matsuoka M; Tsukamoto Y; Makino M
    J Immunol; 2009 Nov; 183(10):6561-8. PubMed ID: 19846882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodegradable nanoparticles containing TLR3 or TLR9 agonists together with antigen enhance MHC-restricted presentation of the antigen.
    Lee YR; Lee YH; Im SA; Yang IH; Ahn GW; Kim K; Lee CK
    Arch Pharm Res; 2010 Nov; 33(11):1859-66. PubMed ID: 21116790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary mucosal immunity mediated through CpG provides adequate protection against pulmonary Mycobacterium tuberculosis infection in the mouse model. A role for type I interferon.
    Troy A; Esparza-Gonzalez SC; Bartek A; Creissen E; Izzo L; Izzo AA
    Tuberculosis (Edinb); 2020 Jul; 123():101949. PubMed ID: 32741537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Codominance of TLR2-dependent and TLR2-independent modulation of MHC class II in Mycobacterium tuberculosis infection in vivo.
    Kincaid EZ; Wolf AJ; Desvignes L; Mahapatra S; Crick DC; Brennan PJ; Pavelka MS; Ernst JD
    J Immunol; 2007 Sep; 179(5):3187-95. PubMed ID: 17709534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-alpha/beta.
    Durand V; Wong SY; Tough DF; Le Bon A
    Immunol Cell Biol; 2004 Dec; 82(6):596-602. PubMed ID: 15550117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of human plasmacytoid dendritic cells by TLR9 impairs Fc gammaRII-mediated uptake of immune complexes and presentation by MHC class II.
    Benitez-Ribas D; Tacken P; Punt CJ; de Vries IJ; Figdor CG
    J Immunol; 2008 Oct; 181(8):5219-24. PubMed ID: 18832675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential use of TLR2 and TLR9 in the regulation of immune responses during the infection with Trypanosoma cruzi.
    Gravina HD; Antonelli L; Gazzinelli RT; Ropert C
    PLoS One; 2013; 8(5):e63100. PubMed ID: 23650544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific.
    Wu J; Meng Z; Jiang M; Zhang E; Trippler M; Broering R; Bucchi A; Krux F; Dittmer U; Yang D; Roggendorf M; Gerken G; Lu M; Schlaak JF
    Immunology; 2010 Mar; 129(3):363-74. PubMed ID: 19922426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IFN-α enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing.
    Spadaro F; Lapenta C; Donati S; Abalsamo L; Barnaba V; Belardelli F; Santini SM; Ferrantini M
    Blood; 2012 Feb; 119(6):1407-17. PubMed ID: 22184405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population.
    Wu CC; Liu SJ; Chen HW; Shen KY; Leng CH
    Oncotarget; 2016 May; 7(21):30804-19. PubMed ID: 27127171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.